266 related articles for article (PubMed ID: 33941878)
1. Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours.
Rodon J; Argilés G; Connolly RM; Vaishampayan U; de Jonge M; Garralda E; Giannakis M; Smith DC; Dobson JR; McLaughlin ME; Seroutou A; Ji Y; Morawiak J; Moody SE; Janku F
Br J Cancer; 2021 Jul; 125(1):28-37. PubMed ID: 33941878
[TBL] [Abstract][Full Text] [Related]
2. Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor.
Ji Y; Huang PH; Woolfenden S; Myers A
Clin Transl Sci; 2022 Jul; 15(7):1713-1722. PubMed ID: 35620969
[TBL] [Abstract][Full Text] [Related]
3. Delivery of the Porcupine Inhibitor WNT974 in Mice.
Zhang LS; Lum L
Methods Mol Biol; 2016; 1481():111-7. PubMed ID: 27590157
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
Boone JD; Arend RC; Johnston BE; Cooper SJ; Gilchrist SA; Oelschlager DK; Grizzle WE; McGwin G; Gangrade A; Straughn JM; Buchsbaum DJ
Lab Invest; 2016 Feb; 96(2):249-59. PubMed ID: 26658453
[TBL] [Abstract][Full Text] [Related]
5. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
Awada A; Eskens FA; Piccart M; Cutler DL; van der Gaast A; Bleiberg H; Wanders J; Faber MN; Statkevich P; Fumoleau P; Verweij J;
Eur J Cancer; 2002 Nov; 38(17):2272-8. PubMed ID: 12441264
[TBL] [Abstract][Full Text] [Related]
8. A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours.
Li X; Qiu M; Wang S; Zhu H; Feng B; Zheng L
Cancer Chemother Pharmacol; 2020 Mar; 85(3):593-604. PubMed ID: 32008115
[TBL] [Abstract][Full Text] [Related]
9. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
10. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
11. Combination of artesunate and WNT974 induces KRAS protein degradation by upregulating E3 ligase ANACP2 and β-TrCP in the ubiquitin-proteasome pathway.
Gong RH; Chen M; Huang C; Wong HLX; Kwan HY; Bian Z
Cell Commun Signal; 2022 Mar; 20(1):34. PubMed ID: 35305671
[TBL] [Abstract][Full Text] [Related]
12. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Gore L; Rothenberg ML; O'Bryant CL; Schultz MK; Sandler AB; Coffin D; McCoy C; Schott A; Scholz C; Eckhardt SG
Clin Cancer Res; 2008 Jul; 14(14):4517-25. PubMed ID: 18579665
[TBL] [Abstract][Full Text] [Related]
16. First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.
Plummer R; Dua D; Cresti N; Drew Y; Stephens P; Foegh M; Knudsen S; Sachdev P; Mistry BM; Dixit V; McGonigle S; Hall N; Matijevic M; McGrath S; Sarker D
Br J Cancer; 2020 Aug; 123(4):525-533. PubMed ID: 32523090
[TBL] [Abstract][Full Text] [Related]
17. Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes.
Guimaraes PPG; Tan M; Tammela T; Wu K; Chung A; Oberli M; Wang K; Spektor R; Riley RS; Viana CTR; Jacks T; Langer R; Mitchell MJ
J Control Release; 2018 Nov; 290():75-87. PubMed ID: 30290244
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP
Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878
[TBL] [Abstract][Full Text] [Related]
19. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
[TBL] [Abstract][Full Text] [Related]
20. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
